Novartis Zometa 8 Mg HCM Retreatment Dose Would Need New Study – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Approval of an 8 mg Zometa dose for retreatment of patients with hypercalcemia of malignancy (HCM) would require a new study as well as additional safety data, FDA said in its Aug. 20 approval letter for a 4 mg dose of Novartis’ zoledronic acid